Specialty Pharma Journal Specialty, Precision & Technology
Amgen and Roche have teamed up to test combining their investigational immunotherapies for patients with breast and colorectal cancer. The companies said that they have formed a collaboration on a Phase Ib study to evaluate the safety and efficacy of Amgen’s investigational oncolytic immunotherapy, talimogene laherparepvec (T-VEC), in combination with …
Tag Archives: T-VEC
June, 2015
May, 2015
-
1 May
FDA Panel Recommends Approval of Amgen’s T-Vec in Melanoma
This week the US Food and Drug Administration (FDA) shared its concerns about the design of Amgen’s study evaluating its experimental melanoma treatment, talimogene laherparepvec (T-VEC), however this did not sway the agency’s advisory panel, which voted overwhelmingly in favor of the drug candidate. The agency’s independent Oncologic Drugs Advisory …